TS-075244 — Problem Acute myeloid leukemia (AML), the most common acute leukemia in adults, is a clinically and molecularly heterogeneous disease. Sequencing of large patient cohorts has uncovered a complex mutational landscape in AML but still fails to completely explain the biological and clinical heterogene…

TS-075231 — Problem Despite recent progress in cancer therapy, acquired resistance to existing cancer drugs reduces therapeutic efficacy. There is a strong need for a therapy with a novel mode of action to overcome drug resistance, and to improve therapeutic efficacy whether used alone or in combination therap…

TS-075185 — Problem The lipolysis-stimulated lipoprotein receptor (LSR) is a promising target for cancer therapy. LSR is overexpressed in many tumor tissues with metastatic signatures such as breast, gastric, and endometrial cancer. LSR expression levels may serve as prognostic indicators and help stratify pat…

TS-075179 — Problem Mitochondria is a promising target for cancer treatment. However, current strategies to specifically and effectively destroy cancer mitochondria in vivo are limited. Solution Applications Competitive Advantages Seeking Opportunities for Licensing and collaboration

TS-075177 — Problem Glioblastoma multiforme (GBM) is the most malignant form of gliomas and the most lethal primary brain tumors in adults. Current biomarkers or clinical features from tissue biopsy samples cannot distinguish glioma true progression from pseudoprogression and might not be suited to monitoring …

TS-075165 — Problem Neuroendocrine tumors (NETs) are often metastatic at diagnosis, thus limiting surgical options. Chemotherapies offer limited efficacy and high toxicity. Meningiomas, though usually benign, are the most common intracranial tumors. Both NETs and meningiomas overexpress SSTR2, making it a prom…

TS-066912 — Targeted humanized mAbs and ADCs for cancer treatment

TS-062605 — The Need: Castration-resistant prostate cancer (CRPC) poses a significant challenge in oncology, with existing therapies often leading to resistance and disease progression. Key drivers of resistance include the androgen receptor (AR) and aldo-keto reductase family 1 member C3 (AKR1C3). Novel treat…

TS-055268 — The laboratory of Dr. Rosa Lapalombella in collaboration with Dr. James Blachly at The Ohio State University has developed a mouse model of spontaneous Chronic Lymphocytic Leukemia.

TS-037968 — The medical physics group in the Department of Radiation Oncology has devised a 6DoF phantom that is the first of its kind to fully integrate multiple routine QA tests specifically for a six degrees-of-freedom linac table.